Hudson Institute’s platform gains international recognition, boosting RNA innovation, research partnerships and biotechnology growth across Australia and Asia-Pacific markets.

Hudson Institute’s RNA technology platform RNAte has received the IMAPAC Overall RNA Upstream Development Excellence Award at the IMAPAC Biopharma Awards 2026, recognising its contribution to advancing RNA therapeutics and strengthening Australia’s biotechnology ecosystem. The RNAte biotech award highlights growing capabilities in RNA product testing, vaccine development support and innovative life sciences research across the Asia-Pacific region.

RNAte Strengthens RNA Innovation Leadership

Established three years ago with seed funding from Invest Victoria and mRNA Victoria, RNAte provides independent testing services that support researchers and companies developing RNA therapeutics and vaccines. The platform has achieved Australia’s first NATA accreditation for RNA product testing and expanded its capabilities to include lipid nanoparticles, antisense oligonucleotides and small-molecule therapeutics.

Key highlights of the RNAte biotech award include:

  • Recognised for RNA upstream development excellence globally

  • Supports RNA therapeutics and vaccine development programs

  • Achieved Australia’s first NATA RNA accreditation

  • Expanded testing across advanced therapeutic platforms

  • Strengthens Asia-Pacific biotechnology collaboration opportunities

Global Recognition Opens New Opportunities

The International Biotech Award presented by IMAPAC also enabled Platform Principal Manager Dr Esther Ling to participate in leading RNA and biopharma conferences in Singapore. The recognition reflects Victoria’s leadership in RNA innovation while creating opportunities for international partnerships and research alliance.

RNAte’s achievement demonstrates Australia’s growing role in the global RNA therapeutics market. The platform continues to support scientists, biotechnology companies and healthcare innovators by providing specialised testing expertise and advancing next-generation medical solutions.

Thus, Business Fortune is of the view that RNAte’s recognition strengthens Australia’s biotechnology future through global collaboration and innovation worldwide.

FAQs

What award did RNAte receive?

RNAte received the IMAPAC Overall RNA Upstream Development Excellence Award.

Who established RNAte?

RNAte was established by the Hudson Institute with support from Invest Victoria and mRNA Victoria.

What services does RNAte provide?

RNAte provides independent testing for RNA therapeutics, vaccines and related technologies.

Why is the award significant?

The award recognises RNAte’s contribution to biotechnology innovation in the Asia-Pacific region.

What technologies does RNAte support?

RNAte supports lipid nanoparticles, antisense oligonucleotides and small-molecule therapeutics.